Cadence Design Systems (NASDAQ: CDNS) announced that Richard Gu, vice president of investor relations, will participate in a fireside chat at the Deutsche Bank Technology Conference.

The session is scheduled for Wednesday, August 26, 2026. Gu will discuss the company’s strategy and market position during the event.

Event Details

The fireside chat will be webcast live at 12:25 pm PDT on August 26, 2026. Investors and analysts can access the live stream online at investor.cadence.com.

Following the live broadcast, the presentation will be archived on Cadence’s website. The recording will remain available for replay for 180 days.

About Cadence

Cadence positions itself as a market leader in AI and digital twins. The company focuses on applying computational software to accelerate innovation in engineering design, ranging from silicon to systems.

Its solutions support leading semiconductor and systems companies building next-generation products for markets including:

• Hyperscale computing
• Mobile communications
• Automotive
• Aerospace
• Industrial
• Life sciences
• Robotics

In 2025, Fortune recognized Cadence as one of the world’s top 100 best companies to work for.

Cadence, a clinical AI company focused on automating chronic disease treatment, announced that its HypertensionOS software has been selected by the U.S. Food and Drug Administration (FDA) as the second participant in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot.

HypertensionOS is classified as prescription software as a medical device (SaMD). It incorporates AI-assisted functionality designed to support clinician-supervised medication initiation and titration for patients diagnosed with Stage 2 hypertension. The system operates within predefined eligibility criteria and deterministic safety checks, intended for use by licensed healthcare professionals with prescriptive authority, such as physicians or Advanced Practice Registered Nurses (APRNs).

Regulatory Context and Scope

The TEMPO pilot was launched by the FDA in connection with the Centers for Medicare & Medicaid Services Innovation Center’s Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) Model. The initiative aims to promote access to specific digital health technologies while safeguarding patient safety and generating real-world evidence on their performance in everyday care.

Participation in the TEMPO pilot does not constitute FDA approval or clearance of HypertensionOS, nor does it represent an FDA determination regarding its safety or effectiveness. The effectiveness of devices selected for TEMPO has not been evaluated by the FDA for the intended uses being evaluated through the pilot.

Operational Foundation

Cadence enters the pilot with an established clinical and operational foundation. The company partners with more than 20 leading health systems and treats over 100,000 active patients with chronic disease. Peer-reviewed research indicates that Cadence drives a 70% relative increase in blood-pressure control among hypertension patients, alongside reductions in hospitalizations and total cost of care across chronic-disease populations.

Through the TEMPO pilot, Cadence plans to generate and report real-world data related to the safety, performance, and patient outcomes associated with HypertensionOS. This evidence is intended to inform how clinical AI systems are built, evaluated, and regulated going forward.

What the Numbers Show

The company’s scale of operations provides a substantial base for the pilot’s data generation. With over 100,000 active patients under management across more than 20 health systems, Cadence has moved beyond early-stage validation to large-scale deployment. The reported 70% relative increase in blood-pressure control suggests that the AI-assisted model is already delivering measurable clinical outcomes at this scale, which will form the core dataset for the FDA’s real-world evidence requirements under TEMPO.